DAL-1 attenuates epithelial- to mesenchymal transition in lung cancer

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Chen, Xianliang ^a   Guan, Xiaoying ^a   Zhang, Huiyu ^a   Xie, Xiaobin ^a   Wang, Hongyan ^a   Long, Jie ^a   Cai, Tonghui ^a   Li, Shuhua ^a   Liu, Zhen ^a   Zhang, Yajie ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Differentially expressed in adenocarcinoma of the lung 1; E cadherin; Epithelial mesenchymal transition; HSPA5; Lung cancer

Indexed keywords

BETA CATENIN; CYTOSKELETON PROTEIN; DIFFERENTIALLY EXPRESSED IN ADENOCARCINOMA OF THE LUNG 1 PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN A5; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ACTIN BINDING PROTEIN; CADHERIN; EPB41L3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; CO IMMUNOPRECIPITATION; CONTROLLED STUDY; DAL 1 GENE; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LUNG CANCER; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ADENOCARCINOMA; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; BIOMARKERS, TUMOR; CADHERINS; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG NEOPLASMS; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; VIMENTIN;

EID: 84988935806     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0117-2     Document Type: Article

References (43)

1. Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S, Agrawal A. Lung cancer biomarkers: State of the art. J Carcinog. 2013;12:3.
2. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818-29.
3. Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 1999;59(1):35-43.
4. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst. 2004;96(4):294-305.
5. Lu B, Di W, Wang H, Ma H, Li J, Zhang Q. Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway. Tumour Biol. 2012;33(6):2007-17.
6. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 2007;103(3):283-91.
7. Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res. 2003;63(19):6320-6.
8. Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res. 2005;11(8):2954-61.
9. Goto A, Niki T, Chi-Pin L, Matsubara D, Murakami Y, Funata N, et al. Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. Cancer Sci. 2005;96(8):480-6.
10. Kuns R, Kissil JL, Newsham IF, Jacks T, Gutmann DH, Sherman LS. Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene. 2005;24(43):6502-15.
11. Busam RD, Thorsell AG, Flores A, Hammarstrom M, Persson C, Obrink B, et al. Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL-1/4.1B). J Biol Chem. 2011;286(6):4511-6.
12. Garufi A, D'Orazi G. High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity. J Exp Clin Cancer Res. 2014;33:79.
13. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21(1):35-43.
14. Soda K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res. 2011;30:95.
15. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591-601.
16. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, et al. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res. 2011;30:115.
17. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol. 2012;22(3):234-49.
18. Jan YH, Tsai HY, Yang CJ, Huang MS, Yang YF, Lai TC, et al. Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3. Cancer Res. 2012;72(19):5119-29.
19. Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33:62.
20. Franco-Chuaire ML, Magda Carolina SC, Chuaire-Noack L. Epithelialmesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin. 2013;54(2):186-205.
21. Richardson F, Young GD, Sennello R, Wolf J, Argast GM, Mercado P, et al. The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res. 2012;32(2):537-52.
22. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012;31(1-2):277-83.
23. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22(7):1197-211.
24. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, et al. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer. 2012;19(3):242-52.
25. Maher ER. Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol. 2013;23(1):10-7.
26. Nunomura W, Denker SP, Barber DL, Takakuwa Y, Gascard P. Characterization of cytoskeletal protein 4.1R interaction with NHE1 (Na (+)/H (+) exchanger isoform 1). Biochem J. 2012;446(3):427-35.
27. Ohno N, Terada N, Komada M, Saitoh S, Costantini F, Pace V, et al. Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1. Biochim Biophys Acta. 2009;1793(3):506-15.
28. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010;9:179.
29. Kittiniyom K, Mastronardi M, Roemer M, Wells WA, Greenberg ER, Titus-Ernstoff L, et al. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer. 2004;40(3):190-203.
30. Gascard P, Parra MK, Zhao Z, Calinisan VR, Nunomura W, Rivkees SA, et al. Putative tumor suppressor protein 4.1B is differentially expressed in kidney and brain via alternative promoters and 5' alternative splicing. Biochim Biophys Acta. 2004;1680(2):71-82.
31. Kang Q, Wang T, Zhang H, Mohandas N, An X. A Golgi-associated protein 4.1B variant is required for assimilation of proteins in the membrane. J Cell Sci. 2009;122(Pt 8):1091-9.
32. Wang H, Liu C, Debnath G, Baines AJ, Conboy JG, Mohandas N, et al. Comprehensive characterization of expression patterns of protein 4.1 family members in mouse adrenal gland: implications for functions. Histochem Cell Biol. 2010;134(4):411-20.
33. Horresh I, Bar V, Kissil JL, Peles E. Organization of myelinated axons by Caspr and Caspr2 requires the cytoskeletal adapter protein 4.1B. J Neurosci. 2010;30(7):2480-9.
34. Buttermore ED, Dupree JL, Cheng J, An X, Tessarollo L, Bhat MA. The cytoskeletal adaptor protein band 4.1B is required for the maintenance of paranodal axoglial septate junctions in myelinated axons. J Neurosci. 2011;31(22):8013-24.
35. Einheber S, Meng X, Rubin M, Lam I, Mohandas N, An X, et al. The 4.1B cytoskeletal protein regulates the domain organization and sheath thickness of myelinated axons. Glia. 2013;61(2):240-53.
36. Cifuentes-Diaz C, Chareyre F, Garcia M, Devaux J, Carnaud M, Levasseur G, et al. Protein 4.1B contributes to the organization of peripheral myelinated axons. PLoS One. 2011;6(9):e25043.
37. Ko BS, Chang TC, Hsu C, Chen YC, Shen TL, Chen SC, et al. Overexpression of 14-3-3epsilon predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology. 2011;58(5):705-11.
38. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser (910)/Ser (935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J. 2010;430(3):405-13.
39. Cheng JC, Klausen C, Leung PC. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett. 2013;329(2):197-206.
40. Kim HJ, Park JW, Cho YS, Cho CH, Kim JS, Shin HW, et al. Pathogenic role of HIF-1alpha in prostate hyperplasia in the presence of chronic inflammation. Biochim Biophys Acta. 2013;1832(1):183-94.
41. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007;67(8):3496-9.
42. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, et al. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006;23(7-8):401-10.
43. Wu HM, Jiang ZF, Fan XY, Wang T, Ke X, Yan XB, et al. Reversed expression of GRIM-1 and GRP78 in human non-small cell lung cancer. Hum Pathol. 2014;45(9):1936-43.